What anxiety medication can be given to a patient with a patent foramen ovale (PFO)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 21, 2025 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

From the Guidelines

For patients with a patent foramen ovale (PFO) who require anxiety medication, physician-prescribed SSRIs or anxiolytics with consideration of side-effect profiles, interactions, response, patient age, and preference are recommended. When managing anxiety in patients with PFO, it is crucial to consider the potential impact of medications on cardiovascular parameters, such as blood pressure and heart rate, to minimize the risk of paradoxical embolism 1.

Key Considerations

  • Selective serotonin reuptake inhibitors (SSRIs) are generally considered safe first-line options for anxiety management in patients with PFO.
  • Benzodiazepines can be used for short-term or acute anxiety management but should be used cautiously due to risks of respiratory depression.
  • Buspirone offers an alternative without significant cardiovascular effects.

Medication Options

  • SSRIs: sertraline (50-200 mg daily), escitalopram (10-20 mg daily), or fluoxetine (20-80 mg daily)
  • Benzodiazepines: lorazepam (0.5-2 mg as needed)
  • Buspirone: 15-60 mg daily in divided doses

Monitoring and Precautions

  • Regular monitoring of cardiovascular parameters is recommended, especially when initiating therapy.
  • Avoid medications that significantly increase blood pressure or heart rate, as these could potentially increase right-to-left shunting through the PFO, as suggested by the management of anxiety and depression in adult survivors of cancer: asco guideline update 1.

From the Research

Anxiety Medication for Patent Foramen Ovale

  • The treatment of anxiety in patients with patent foramen ovale (PFO) may involve the use of various medications, including selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) 2, 3.
  • A case report suggests that Paroxetine, an SSRI, may be effective in improving symptoms of anxiety and depression in a patient with PFO 4.
  • Other medications such as Oxazepam and Olanzapine may also be used to treat anxiety in patients with PFO 4.
  • The choice of medication will depend on the individual patient's needs and medical history, and should be made in consultation with a healthcare professional.
  • It is worth noting that the relationship between PFO and anxiety is not fully understood, and further research is needed to determine the best course of treatment for patients with this condition 4, 5, 6.

Mechanism of Action

  • SNRIs, such as venlafaxine and duloxetine, work by inhibiting the reuptake of serotonin and norepinephrine, two neurotransmitters that play a key role in mood regulation 3.
  • SSRIs, such as paroxetine, work by inhibiting the reuptake of serotonin, which can help to improve mood and reduce symptoms of anxiety and depression 3.
  • The use of these medications in patients with PFO may help to improve symptoms of anxiety and depression, and may also have a positive effect on hypoxemia 4.

Potential Benefits and Risks

  • The use of SNRIs and SSRIs in patients with PFO may have several potential benefits, including improved symptoms of anxiety and depression, and improved hypoxemia 2, 3, 4.
  • However, these medications may also have potential risks and side effects, such as nausea, dizziness, and changes in blood pressure 3.
  • Patients with PFO should be closely monitored by a healthcare professional when taking these medications, and should report any changes in their symptoms or side effects.

Related Questions

What are alternatives to Selective Serotonin Reuptake Inhibitors (SSRIs) for treating anxiety and Premenstrual Dysphoric Disorder (PMDD)?
What are the clinical implications of alpha‑adrenergic receptor down‑regulation caused by selective serotonin reuptake inhibitors (SSRIs)?
What are the key points to discuss when counseling patients about antidepressants, such as Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), and Tricyclic Antidepressants (TCAs)?
What antidepressants have a low risk of causing hyperhidrosis (excessive sweating)?
What is the best antidepressant for a patient with depression, anxiety, and ADHD, with Type 2 DM, taking Mounjaro (tirzepatide), Jardiance (empagliflozin), Elavil (amitriptyline), gabapentin, pravastatin, ramipril, Trulicity (dulaglutide), and Basaglar (insulin glargine)?
What is the diagnosis and treatment for Stercoral colitis (inflammatory bowel disease)?
What can treat Candida parapsilosis onychomycosis of the toenails that did not respond to Jublia (efinaconazole)?
When to stop subcutaneous (under the skin) Heparin (unfractionated heparin) before surgery?
What labs are important to check in a patient with hyperparathyroidism (Hyperparathyroidism) of renal (Kidney) origin, specifically those with impaired renal function and hypercalcemia?
What is the role of Lovenox (Enoxaparin) in the treatment of Pulmonary Embolism?
What are the alternatives for tick prophylaxis in a patient with an allergy to doxycycline (Doxycycline)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.